Brief: Celyad Oncology End-Sept Cash, Cash Equivalents Of EUR 2.3 Million
09/11/2023 06:17
Nov 9 (Reuters) - Celyad Oncology SA CYAD.BR :
* PUBLICATION OF DATA DETAILING DEVELOPMENT OF OUR MICRORNA
(MIRNA)-BASED MULTIPLEX SHRNA APPROACH, WHICH ALLOWS TO
DOWN-REGULATE SEVERAL GENES SIMULTANEOUSLY, IN MOLECULAR THERAPY
- NUCLEIC ACIDS
* TODAY REPORTS ITS FINANCIAL RESULTS FOR Q3 OF 2023
* AS OF SEPTEMBER 30, 2023, COMPANY HAD CASH AND CASH
EQUIVALENTS
OF EUR 2.3 MILLION.
* COMPANY PROJECTS THAT ITS EXISTING CASH AND CASH
EQUIVALENTS
SHOULD BE SUFFICIENT TO FUND OPERATING EXPENSES AND CAPITAL
EXPENDITURE REQUIREMENTS INTO Q1 OF 2024.
* CONTINUES TO PROJECT THAT EXISTING CASH AND CASH
EQUIVALENTS
WILL NOT BE SUFFICIENT TO FUND ITS ESTIMATED OPERATING AND
CAPITAL EXPENDITURES OVER AT LEAST NEXT 12 MONTHS FROM DATE THAT
THIS RELEASE IS ISSUED.
Source text for Eikon: ID:nGNX1S0901
Further company coverage: CYAD.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))